Cerenome (CNSY) Stock Overview
A clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 5/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
CNSY Community Fair Values
Create NarrativeSee what 20 others think this stock is worth. Follow their fair value or set your own to get alerts.
Analyst Price Targets
Cerenome, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.03 |
| 52 Week High | US$23.43 |
| 52 Week Low | US$2.00 |
| Beta | 1.39 |
| 1 Month Change | -33.88% |
| 3 Month Change | -50.25% |
| 1 Year Change | -80.82% |
| 3 Year Change | -93.50% |
| 5 Year Change | -99.71% |
| Change since IPO | -99.90% |
Recent News & Updates
Narrative Update • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.
Narrative Update • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.
Narrative Update • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.Narrative Update • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.Recent updates
Narrative Update • Sep 11
CNSY: CNS Delivery Platform And CSF Assay Expansion Will Drive Future Upside
Analysts have reset their price target for Cerenome from $38.00 to $32.50, reflecting updated assumptions on higher projected revenue growth, wider profit margins, a slightly higher discount rate, and a lower future P/E multiple. What’s in the News for Cerenome Cerenome plans a private placement of senior secured convertible notes with 3i, LP with an aggregate original principal amount of US$21,276,596 at a 6% original issue discount, for expected proceeds of about US$20,000,000.24.Narrative Update • Jul 06
PSTV: CNSide Coverage And Rebranding Will Reprice Future CNS Oncology Shares
Analysts have trimmed their 12 month price target on Plus Therapeutics to $57 from $65, citing updated fair value assumptions, a modestly higher discount rate, and revised estimates for future revenue growth, profit margins, and P/E multiples. What’s in the News for Plus Therapeutics Plus Therapeutics announced a corporate rebranding to Cerenome, with its Nasdaq ticker expected to change from PSTV to CNSY effective August 3, 2026, according to its mid year business update.Narrative Update • Jun 22
PSTV: CNS Oncology Pipeline And New CPT Code Will Drive Upside
Analysts have adjusted their fair value estimate for Plus Therapeutics stock from $1 to $12, citing updated assumptions around discount rates, revenue growth, profit margins and a lower future P/E multiple as key drivers of the new price target framework. Analyst Commentary Recent Street research on Plus Therapeutics signals a more cautious tone, with bearish analysts revisiting their assumptions around valuation, execution risk and the pace at which the company may be able to translate its pipeline into financial results.Narrative Update • Jun 08
PSTV: Future CNS Oncology CPT Codes Will Reprice Shares Despite Downgrades
Analysts have reduced their price target on Plus Therapeutics by $25.50, reflecting updated views on the company’s growth prospects and risk profile following recent research revisions from the Street. Analyst Commentary Recent Street research on Plus Therapeutics highlights a mix of caution and potential upside, with price targets and ratings being recalibrated to reflect updated views on execution risk and commercialization timelines.Narrative Update • May 24
PSTV: Future Brain Cancer CPT Codes Could Reprice Shares Despite Recent Downgrades
Analysts have cut their price target on Plus Therapeutics by $25.50, citing updated assumptions around discount rates, revenue growth, profit margins, and future P/E multiples following recent downgrades and target revisions. Analyst Commentary Recent research notes highlight a shift in how analysts frame the risk and reward around Plus Therapeutics.Narrative Update • May 02
PSTV: CNS Delivery And New CPT Codes Will Drive Future Upside
Analysts have adjusted their view on Plus Therapeutics, cutting the average price target by $25.50 while updating their models for fair value, discount rate, profit margin and future P/E to reflect a mix of rating changes and new coverage. Analyst Commentary Recent Street research on Plus Therapeutics reflects a mix of optimism about long term potential and caution around execution and valuation, with one firm initiating coverage positively and others resetting expectations through a downgrade and a lower price target.Narrative Update • Apr 18
PSTV: Future Brain Cancer CPT Codes And Delivery Technique Could Reprice Shares
Narrative Update The updated analyst price target for Plus Therapeutics moves from about $475 to roughly $65, as analysts cite recent target cuts and a downgrade, along with one newer bullish initiation that together lead to a more tempered but still constructive set of assumptions on revenue growth, margins, and future P/E. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of caution and optimism, with several firms trimming targets and one newer, more constructive initiation helping to reset expectations rather than support extreme outcomes.Narrative Update • Apr 03
PSTV: Future Brain Cancer CPT Code And FDA Dialogue Could Reprice Shares
The analyst price target for Plus Therapeutics has shifted from $20.50 to $475.00, reflecting updated views on fair value, discount rate, revenue growth, profit margin, and future P/E. This change is informed by recent mixed Street research that includes a downgrade from D.Narrative Update • Mar 20
PSTV: Upcoming CNS Milestones And New CPT Code Will Shape Upside Potential
Narrative Update on Plus Therapeutics Analysts have trimmed their price targets on Plus Therapeutics by about $1 to $1.50, reflecting revised views on profit margin potential and valuation, while still citing supportive research coverage for the story. Analyst Commentary Recent research updates paint a mixed picture for Plus Therapeutics, with one initiation taking a constructive stance and other reports trimming price targets by $1 to $1.50.Narrative Update • Mar 06
PSTV: FDA Pivotal Trial Design And Brain Cancer Pipeline Will Drive Upside
Analysts have reduced their blended price target on Plus Therapeutics by about $0.60, reflecting updated views on fair value, revenue growth expectations, profit margins, and future P/E following recent initiations and target changes from several firms. Analyst Commentary Recent Street research on Plus Therapeutics shows a mix of views, with some firms starting coverage positively while others are taking a more conservative stance through reduced price targets.Narrative Update • Feb 19
PSTV: Upcoming CNS Milestones And Diagnostics Rollout Will Drive Future Upside
Analysts have trimmed their average Plus Therapeutics price target by $2.50, citing updated assumptions around discount rates, profit margins and a higher future P/E multiple, while still maintaining their fair value estimate at $5.50. Analyst Commentary Bullish Takeaways Bullish analysts point to enough upside against the current trading price to justify a fresh positive view, even after trimming inputs such as discount rates and profit margins.Narrative Update • Feb 05
PSTV: Upcoming CNS Trials And Diagnostics Expansion Will Drive Upside Potential
Analysts have revised their price targets for Plus Therapeutics lower, with the implied fair value estimate moving from about $9.67 to $5.50 as they incorporate updated assumptions for revenue growth, profit margins, discount rates, and a lower future P/E multiple following recent research updates. Analyst Commentary Recent research updates offer a mixed picture of how analysts are thinking about Plus Therapeutics, with some seeing attractive upside potential and others tempering expectations through lower price targets.Narrative Update • Jan 22
PSTV: FDA Pivotal Trial Progress Will Drive Future Upside Potential
Narrative Update on Plus Therapeutics Analysts have adjusted their price target for Plus Therapeutics to US$1.63. The change is linked to updated assumptions for discount rate, revenue growth, profit margin, and a revised forward P/E of 49.25x, which reflect their refreshed outlook on the company’s risk and earnings potential.Narrative Update • Jan 06
PSTV: Advancing Central Nervous System Cancer Trials And Grant Funding Will Drive Upside Potential
Analysts have raised their price target on Plus Therapeutics to US$1.63 per share, reflecting updated assumptions that now pair a revenue growth estimate of 96.95% with a slightly higher discount rate of 7.18%, a lower future P/E of 51.69x, and a modestly adjusted profit margin outlook of 16.24%. What's in the News Presented three clinical data updates at the WFNOS/SNO Annual Meeting in Honolulu covering multiple doses of Rhenium (186Re) Obisbemeda (Reyobiq) for leptomeningeal metastases, including rationale, design, and preliminary Cohort 1 data (Key Developments).Narrative Update • Dec 15
PSTV: Expanded Brain Cancer Pipeline And Funding Will Drive Upside Potential
Narrative Update on Plus Therapeutics Analysts have raised their price target on Plus Therapeutics to approximately 83.96 from about 114.72, citing a modestly higher assumed discount rate, slightly lower long term profit margins, and somewhat stronger revenue growth expectations that together point to a more balanced, though still optimistic, valuation profile. What's in the News Presented three positive clinical data updates at the WFNOS/SNO Annual Meeting, including early ReSPECT-LM multidose trial results showing REYOBIQ was well tolerated at initial dosing levels and supporting continued dose optimization for leptomeningeal metastases patients (company announcement).Narrative Update • Nov 04
PSTV: 15 Million Financing And Prefunded Warrants Will Drive Clinical Progress
Analysts have raised their fair value estimate for Plus Therapeutics from $7.88 to $9.67, citing updated revenue forecasts and improved capital structure following recent changes in financing. Analyst Commentary Analyst updates on Plus Therapeutics reflect a balanced perspective on the company’s outlook and recent financing changes.Narrative Update • Sep 04
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Analysts lowered their price target for Plus Therapeutics from $8.83 to $7.88 primarily due to anticipated equity dilution from recent financing, which increased outstanding shares and warrants, though they remain positive on the company’s long-term outlook. Analyst Commentary Price target reductions reflect anticipated equity dilution following recent financing activities.Analysis Article • Aug 15
We Think Plus Therapeutics (NASDAQ:PSTV) Needs To Drive Business Growth Carefully
NasdaqCM:PSTV 1 Year Share Price vs Fair Value Explore Plus Therapeutics's Fair Values from the Community and select...
New Narrative • Apr 20
15 Million Financing And Oncology Trials Will Secure Clinical Progress
Strengthened financial position and leadership could drive clinical advancements, potentially boosting future revenue and improving earnings growth.Shareholder Returns
| CNSY | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -6.5% | 0.3% | -0.1% |
| 1Y | -80.8% | 36.3% | 11.9% |
Return vs Industry: CNSY underperformed the US Biotechs industry which returned 36.3% over the past year.
Return vs Market: CNSY underperformed the US Market which returned 11.9% over the past year.
Price Volatility
| CNSY volatility | |
|---|---|
| CNSY Average Weekly Movement | 9.7% |
| Biotechs Industry Average Movement | 9.5% |
| Market Average Movement | 6.8% |
| 10% most volatile stocks in US Market | 15.1% |
| 10% least volatile stocks in US Market | 2.9% |
Stable Share Price: CNSY has not had significant price volatility in the past 3 months compared to the US market.
Volatility Over Time: CNSY's weekly volatility has decreased from 16% to 10% over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1996 | 28 | Marc Hedrick | cerenome.com |
Cerenome, Inc., a clinical-stage pharmaceutical company, focuses on the development, manufacture, and commercialization of treatments for patients with cancer. The company’s lead radiotherapeutic candidate is rhenium obisbemeda, a patented radiotherapy for patients with central nervous system and other cancers, including recurrent glioblastoma, leptomeningeal metastases, and pediatric brain cancers. It also develops Rhenium-188 NanoLiposome Biodegradable Alginate Microsphere to treat various solid organ cancers, such as primary and secondary liver cancers, by intra-arterial injection.
Cerenome, Inc. Fundamentals Summary
| CNSY fundamental statistics | |
|---|---|
| Market cap | US$15.41m |
| Earnings (TTM) | -US$26.09m |
| Revenue (TTM) | US$4.20m |
3.7x
P/S Ratio-0.6x
P/E RatioIs CNSY overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| CNSY income statement (TTM) | |
|---|---|
| Revenue | US$4.20m |
| Cost of Revenue | US$12.51m |
| Gross Profit | -US$8.30m |
| Other Expenses | US$17.78m |
| Earnings | -US$26.09m |
Last Reported Earnings
Jun 30, 2026
Next Earnings Date
n/a
| Earnings per share (EPS) | -3.44 |
| Gross Margin | -197.57% |
| Net Profit Margin | -620.70% |
| Debt/Equity Ratio | 0% |
How did CNSY perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2026/09/21 17:50 |
| End of Day Share Price | 2026/09/18 00:00 |
| Earnings | 2026/06/30 |
| Annual Earnings | 2025/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Cerenome, Inc. is covered by 11 analysts. 4 of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Edward Woo | Ascendiant Capital Markets LLC |
| Andrew D'Silva | B. Riley Securities, Inc. |
| John Savin | Edison Investment Research |